Tackling the EGFR in pathological tissue remodelling
- 28 February 2006
- journal article
- review article
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 19 (1) , 74-78
- https://doi.org/10.1016/j.pupt.2005.04.005
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Matrix metalloproteinases as modulators of inflammation and innate immunityNature Reviews Immunology, 2004
- Agonist-Induced Activation of Matrix Metalloproteinase-7 Promotes Vasoconstriction Through the Epidermal Growth Factor–Receptor PathwayCirculation Research, 2004
- Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cellsJournal of Cellular Physiology, 2003
- PKC‐ζ is required for angiotensin II‐induced activation of ERK and synthesis of C‐FOS in MCF‐7 cellsJournal of Cellular Physiology, 2003
- Cardiac Hypertrophy: The Good, the Bad, and the UglyAnnual Review of Physiology, 2003
- Transactivation of ErbB1 and ErbB2 receptors by angiotensin II in normal human prostate stromal cellsThe Prostate, 2002
- Metalloprotease inhibitor blocks angiotensin II-induced migration through inhibition of epidermal growth factor receptor transactivationBiochemical and Biophysical Research Communications, 2002
- Angiotensin II-induced growth of vascular smooth muscle cells requires an Src-dependent activation of the epidermal growth factor receptorKidney International, 2000
- Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptorsNature, 1996
- Alterations of Angiotensin II Receptor Contents in Hypertrophied HeartsBiochemical and Biophysical Research Communications, 1995